Given Moderna is testing a candidate mRNA influenza vaccine, I would suspect that they are well into working on the computing capacity. The shorter manufacturing time would give a strong advantage to mRNA flu shots (because they could be made later when we have more information about likely circulating strains).

As for infection after vaccination, I do wonder how much getting an asymptomatic or mild delta infection boosts the protection of vaccinated people.